The Hyperhidrosis Market

Hyperhidrosis is a disorder of excessive sweating beyond what is expected for thermoregulatory needs and environmental conditions. Primary hyperhidrosis (under arms, hands and feet) affects approximately 4.8% of the US population, or roughly 15.3 million people, and is caused by an overactive cholinergic response of the sweating glands. Several studies have demonstrated that excessive sweating often disrupts normal daily activities and can result in occupational, emotional, psychological, social and physical impairment.

The market for products to control sweating is large and highly underpenetrated by prescription pharmaceutical products. More specifically, patients who seek treatment from a physician most commonly receive prescription topical antiperspirants, as a first-line option; however, their use is limited by modest efficacy and skin irritation, particularly in patients with more severe disease. As second-line alternatives, patients are directed to more invasive treatment regimens and procedures that aim to block, destroy or remove the sweat glands. Such treatment options have limitations in their efficacy, significant side effects and/or are invasive and costly.

Accordingly, we believe that the market opportunity for a new, effective, well-tolerated topical hyperhidrosis treatment is substantial, and that such a therapy could not only further penetrate the segment of patients who currently seek treatment from a physician, but encourage more patients to seek treatment.